Alzheimers disease
Conditions
Interventions
Gold Standard:Aß-PET or CSF
Index test:CSF: Decreased Aß42/40 ratio accompanied by elevated phosphorylated tau (p-tau).Aß-PET: A noninvasive imaging modality that visualizes the distribution and burden of amyloid-ß deposition in
Sponsors
Zhejiang Provincial People's Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Individuals presenting with subjective complaints of cognitive impairment and memory decline. 2.Patients with clinical features suggestive of Alzheimer’s disease or mild cognitive impairment (MCI). 3.High-risk individuals with a family history of Alzheimer’s disease. 4.Individuals who voluntarily agree to undergo blood testing and provide written informed consent.
Exclusion criteria
Exclusion criteria: 1.Patients with severe coagulation disorders. 2.Patients with major systemic diseases that may affect blood-based biomarkers (e.g., severe hepatic or renal insufficiency). 3.Patients who are unable to comply with sample collection procedures or who refuse testing. 4.Individuals who refuse to provide written informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood-based AD biomarkers (Aß1–42, Aß1–40, Aß42/40 ratio, p-tau181, and p-tau217);Diagnostic performance of blood-based AD biomarker testing (area under the curve, AUC).; | — |
Secondary
| Measure | Time frame |
|---|---|
| Correlation between blood-based AD biomarkers and Aß-PET or cerebrospinal fluid (CSF) findings.; | — |
Countries
China
Contacts
Public ContactSheng Zhang
Zhejiang Provincial People's Hospital
Outcome results
None listed